-
公开(公告)号:US20230002401A1
公开(公告)日:2023-01-05
申请号:US17741050
申请日:2022-05-10
发明人: Annekatrin Charlotte HEIMANN , Sandra Ruth HANDSCHUH , Christoph HOENKE , Christian GNAMM , Cédrickx GODBOUT , Patrick GROSS , Joerg KLEY , Christian Andreas KUTTRUFF , Dirk REINERT , Raphael STUBER
IPC分类号: C07D491/048
摘要: The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
-
公开(公告)号:US20230000878A1
公开(公告)日:2023-01-05
申请号:US17741009
申请日:2022-05-10
发明人: Annekatrin Charlotte HEIMANN , Sandra Ruth HANDSCHUH , Christoph HOENKE , Cédrickx GODBOUT , Christian GNAMM , Patrick GROSS , Joerg KLEY , Christian Andreas KUTTRUFF , Dirk REINERT , Raphael STUBER
IPC分类号: A61K31/5386 , A61K39/395 , A61K45/06 , A61K31/496 , A61K31/4412 , C07D491/048 , A61K31/5377 , A61K31/519 , C07D519/00 , A61P37/06
摘要: The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds
for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).-
公开(公告)号:US20240208997A1
公开(公告)日:2024-06-27
申请号:US18386979
申请日:2023-11-03
发明人: Annekatrin Charlotte HEIMANN , Alexander DREYER , Christian GNAMM , Cédrickx GODBOUT , Marc Alexander GRUNDL , Sandra Ruth HANDSCHUH , Christoph HOENKE , Joerg Thomas KLEY , Christian Andreas KUTTRUFF , Jun LI , Dirk REINERT , Raphael STUBER
IPC分类号: C07D498/22 , A61K45/06 , C07D491/048
CPC分类号: C07D498/22 , A61K45/06 , C07D491/048
摘要: The invention relates to compounds of formula I
wherein R1, R2, R3, A, D, E, G, J, K and L are defined as in claim 1, and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof, for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonopathies, non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).-
公开(公告)号:US20240189315A1
公开(公告)日:2024-06-13
申请号:US18501509
申请日:2023-11-03
发明人: Annekatrin Charlotte HEIMANN , Christian GNAMM , Cédrickx GODBOUT , Sandra Ruth HANDSCHUH , Christoph HOENKE , Joerg Thomas KLEY , Christian Andreas KUTTRUFF , Jun LI , Dirk REINERT , Raphael STUBER , Theodor THEIS
IPC分类号: A61K31/529 , A61K31/4418 , A61K31/496 , A61K39/395 , A61K45/06 , C07D498/22
CPC分类号: A61K31/529 , A61K31/4418 , A61K31/496 , A61K39/3955 , A61K45/06 , C07D498/22
摘要: The invention relates to compounds of formula I
wherein R1, R2, R3, R4, A, D, E, G, J, K and L are defined as in claim 1, and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof, for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonopathies, non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
-
-
-